Onset of Vitiligo Within Patients Receiving Immune Checkpoint Inhibitors: An Evidence-Based Review

J Cutan Med Surg. 2024 Jul-Aug;28(4):396-397. doi: 10.1177/12034754241239250. Epub 2024 Mar 11.

Authors

Ahmed Bagit¹, Muskaan Sachdeva², Siddhartha Sood¹, Edgar Akuffo-Addo¹, Sauliha Alli¹, Khalad Maliyar², Jorge R Georgakopoulos², Asfandyar Mufti^{3

4}, Jensen Yeung^{2

3

4

5}

Affiliations

¹ Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
² Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
³ Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
⁴ Division of Dermatology, Women's College Hospital, Toronto, ON, Canada.
⁵ Probity Medical Research, Waterloo, ON, Canada.

PMID: 38468185
DOI: 10.1177/12034754241239250

No abstract available

Keywords: CTLA-4; PD-1; PD-L1; adverse events; cutaneous; immune checkpoint inhibitors; melanoma; vitiligo.

Publication types

Letter
Review
Systematic Review

MeSH terms

Humans
Immune Checkpoint Inhibitors* / adverse effects
Vitiligo* / chemically induced

Substances

Immune Checkpoint Inhibitors